Bipolar I Disorder is a recurrent, often lifelong mood disorder defined by at least one manic episode, with depressive and hypomanic episodes the rule rather than the exception across the lifetime course. The DSM-5-TR places it in the Bipolar and Related Disorders chapter, sitting nosologically between schizophrenia-spectrum illness and major depressive disorder; ICD-11 organizes the same construct under chapter 06 mood disorders with broadly congruent criteria. It carries one of the highest suicide rates in psychiatry and substantial functional and medical morbidity, including a meaningful loss of life expectancy from cardiovascular disease. Diagnosis hinges on a careful longitudinal history rather than the cross-sectional presentation, since most patients first present in a depressive episode and the manic history must be elicited. Treatment is staged by phase — acute mania, acute bipolar depression, and maintenance — with Lithium, certain anticonvulsants, and several second-generation antipsychotics as the pharmacologic backbone, supplemented by psychoeducation and structured psychotherapies. The bottom line: identify the manic history, treat the phase you have, and protect the long arc with a maintenance regimen the patient can actually live with.

Bipolar I is uncommon in absolute terms but disproportionately costly because of its early onset, recurrence, and suicide risk. Population-level estimates are sensitive to whether subthreshold presentations are included.

Prevalence and incidence

• Lifetime prevalence of Bipolar I in U.S. community samples is approximately 1.0%, with 12-month prevalence near 0.6% in the National Comorbidity Survey Replication.¹
• Cross-national WHO World Mental Health surveys converge on a lifetime prevalence of about 0.6% for Bipolar I and 1.0% for the broader bipolar spectrum, with consistent disability across high- and middle-income countries.²
• The male-to-female ratio for Bipolar I is approximately 1:1, in contrast to the female preponderance seen in Bipolar II.³

Age of onset

• Mean age of onset is in the late teens to mid-twenties, with a median around 18-20 years; later first episodes occur but should prompt a careful search for medical or substance-related contributors.^1,3
• Earlier onset is associated with greater familial loading, more mixed features, higher comorbidity, and worse long-term outcome.³

Comorbidity

• Lifetime comorbidity with at least one anxiety disorder exceeds 60%, and with substance use disorders approaches 40-60%, with alcohol use disorder the most common.^1,4
• Attention-deficit/hyperactivity disorder, eating disorders, and personality disorders (especially borderline) are overrepresented and complicate diagnosis and treatment.^3-4
• Cardiovascular disease, metabolic syndrome, and obesity are markedly more prevalent than in the general population and account for most of the excess mortality.⁵

Suicide and mortality

• Lifetime suicide attempt rates approach 30-40%, and suicide mortality is roughly 10-30 times that of the general population, among the highest of any psychiatric disorder.^5-6
• All-cause mortality is elevated approximately twofold, with cardiovascular disease the leading non-suicide contributor and a life-expectancy gap of roughly 10-15 years.⁵

Risk factors

• Family history is the strongest single risk factor; a first-degree relative with Bipolar I confers an approximately 5-10 fold increase in risk.^3,7
• Childhood adversity, perinatal complications, cannabis use, and traumatic brain injury have all been associated with earlier onset or worse course in cohort studies.^3,7

No single mechanism explains Bipolar I. The most defensible model is a polygenic vulnerability that interacts with stress, sleep disruption, and substance exposure to destabilize cortico-limbic circuits regulating mood, reward, and circadian rhythm.

Genetics

• Twin heritability estimates cluster around 60-85%, among the highest in psychiatry.^7-8
• Genome-wide association studies have identified dozens of common variants of small effect, with substantial polygenic overlap with schizophrenia and major depressive disorder.⁸
• No single gene has clinically actionable predictive value; pharmacogenomic testing is not routinely indicated for diagnosis or first-line drug selection.⁹

Neurochemistry

• Dopaminergic hyperactivity in mesolimbic pathways is the most consistent neurochemical correlate of mania, supported by the manic effects of stimulants, levodopa, and dopamine agonists, and the antimanic effect of dopamine antagonists.¹⁰
• Serotonergic hypofunction and noradrenergic dysregulation are implicated in bipolar depression, but the picture is less clean than in unipolar depression and antidepressant monotherapy can destabilize mood.¹⁰
• Glutamatergic abnormalities, particularly in the anterior cingulate and prefrontal cortex, are implicated by magnetic resonance spectroscopy and by the rapid antidepressant action of ketamine in bipolar depression.^10-11

Neurocircuitry and imaging

• Functional imaging shows hyperactivity of the amygdala and ventral striatum with hypoactivity of the ventrolateral and dorsolateral prefrontal cortex during emotional and reward processing.¹¹
• Structural studies report ventricular enlargement, white-matter hyperintensities, and reduced volume in the prefrontal cortex and hippocampus; effect sizes are modest and overlap with other severe mental illnesses.¹¹
• The default mode network shows abnormal connectivity in both manic and depressive phases, consistent with disrupted self-referential and emotional processing.¹¹

Circadian and chronobiologic factors

• Sleep loss is a well-documented mania trigger, and circadian rhythm instability is a candidate trait marker.¹²
• Lithium, valproate, and several second-generation antipsychotics modulate molecular clock genes and may exert part of their effect through circadian stabilization.¹²

Integrative model

• A defensible synthesis: polygenic vulnerability lowers the threshold for cortico-limbic dysregulation; environmental insults (sleep loss, substance use, stress, antidepressant exposure) push the system into mania or depression; recurrent episodes drive progressive functional and possibly neural change, the so-called kindling and neuroprogression hypotheses, which remain incompletely validated.^10-11

Bipolar I requires at least one lifetime manic episode; depressive and hypomanic episodes are not required for the diagnosis but are nearly universal across the course. The DSM-5-TR threshold for mania is the combination of a sustained mood and energy change with functional impact severe enough to require hospitalization, produce psychotic features, or cause marked dysfunction.

Manic episode (DSM-5-TR)

• A distinct period of abnormally and persistently elevated, expansive, or irritable mood with abnormally and persistently increased goal-directed activity or energy, lasting at least one week and present most of the day, nearly every day, or any duration if hospitalization is required.¹³
• Three or more of the following (four if mood is only irritable): inflated self-esteem or grandiosity, decreased need for sleep, pressured speech, flight of ideas or racing thoughts, distractibility, increased goal-directed activity or psychomotor agitation, and excessive involvement in activities with high potential for painful consequences.¹³
• The disturbance causes marked impairment in social or occupational functioning, requires hospitalization to prevent harm, or includes psychotic features.¹³
• Symptoms are not attributable to a substance or another medical condition; an episode that emerges during antidepressant treatment and persists beyond the physiologic effect of the drug counts as a manic episode and supports the bipolar diagnosis.¹³

Hypomanic episode

• Same symptom set as mania but lasting at least four consecutive days, with an unequivocal change observable by others, and without marked impairment, hospitalization, or psychotic features.¹³
• Hypomania alone does not satisfy Bipolar I; a single lifetime manic episode does.¹³

Major depressive episode in Bipolar I

• Five or more of nine depressive symptoms during the same two-week period, with at least one being depressed mood or anhedonia, producing distress or impairment.¹³
• Symptom set: depressed mood, anhedonia, weight or appetite change, sleep disturbance, psychomotor change, fatigue, worthlessness or guilt, impaired concentration, and recurrent thoughts of death or suicidality.¹³
• Bipolar depression is more often characterized by atypical features (hypersomnia, hyperphagia, leaden paralysis), psychomotor retardation, and earlier onset than unipolar depression, though no single feature is diagnostic.¹⁴

Specifiers

• Current or most recent episode: manic, hypomanic, depressed, or unspecified.¹³
• With anxious distress, with mixed features, with rapid cycling (four or more episodes in 12 months), with melancholic features, with atypical features, with mood-congruent or mood-incongruent psychotic features, with catatonia, with peripartum onset, and with seasonal pattern.¹³
• Severity: mild, moderate, severe; in partial remission; in full remission.¹³

ICD-11 differences

• ICD-11 Bipolar type I requires at least one manic or mixed episode and uses a similar duration threshold; the criteria are operationally close to DSM-5-TR but ICD-11 retains a distinct mixed episode category rather than the mixed-features specifier.¹⁵
• ICD-11 reorganized mood disorders under chapter 06 in 2022.¹⁵

Bipolar I is an episodic illness with substantial inter-episode morbidity. Patients spend more time depressed than manic over the long course, which has direct treatment implications.

Manic presentation

• Pressured speech, decreased sleep without fatigue, grandiosity, hyperactivity, and impaired judgment with high-risk behavior (spending, sexual indiscretion, reckless driving) are the prototypical features.^13-14
• Psychotic features are present in roughly half of manic episodes that lead to hospitalization, most often mood-congruent grandiose or persecutory delusions.¹⁴
• Irritable mania, particularly with mixed features, is more common than the classic euphoric presentation in clinical samples and is associated with greater suicide risk.¹⁴

Depressive presentation

• Most patients first present in a depressive episode, and bipolar depression is misclassified as unipolar depression in roughly 30-40% of patients for years before correct diagnosis.^14,16
• Features that should raise suspicion for bipolarity include early age of onset, multiple prior depressive episodes, atypical neurovegetative features, postpartum onset, family history of bipolar disorder, antidepressant-induced activation, and brief recurrent depressions.^14,16

Mixed features

• Co-occurrence of full criteria for one polarity with at least three contrastingsymptoms of the other defines the mixed-features specifier and predicts greater suicide risk and poorer treatment response to antidepressants alone.^13-14

Course

• Episodes are recurrent: untreated, episode frequency tends to increase and inter-episode intervals shorten over time, the kindling pattern.¹⁴
• Inter-episode subsyndromal depressive and cognitive symptoms persist in a substantial minority and drive functional disability more than acute episodes.¹⁶

Red flags for occult bipolarity in a depressed patient:

• Early onset depression, recurrent brief depressions, postpartum psychosis, treatment-resistant depression, antidepressant-induced hypomania or rapid cycling, and a strong family history of bipolar disorder or completed suicide.^14,16

The differential is wide because mania is a syndromic state that medical, neurologic, and substance-induced conditions can mimic. The most common diagnostic error in clinical practice is missing the manic history in a patient presenting with depression.

Primary psychiatric differentials

• Major depressive disorder: distinguished by the absence of any lifetime manic or hypomanic episode; longitudinal history is essential.^14,16
• Bipolar II disorder: at least one hypomanic and one major depressive episode without any manic episode.¹³
• Cyclothymic disorder: chronic fluctuating subthreshold depressive and hypomanic symptoms over at least two years without meeting full episode criteria.¹³
• Schizoaffective disorder, bipolar type: psychotic symptoms persist for at least two weeks in the absence of a mood episode at some point in the lifetime course.¹³
• Schizophrenia: chronic psychosis with prominent negative symptoms; mood episodes, if present, are brief relative to the total course.¹³
• Borderline personality disorder: affective instability is rapid (hours to days) and reactive to interpersonal triggers, without the sustained energy and sleep changes of mania.¹⁴
• Attention-deficit/hyperactivity disorder: chronic inattention and overactivity from childhood without discrete episodes of euphoric or irritable mood.¹⁴

Substance-induced presentations

• Stimulants (cocaine, methamphetamine, prescription stimulants), corticosteroids, levodopa, dopamine agonists, anabolic steroids, hallucinogens, and antidepressants can all precipitate manic-like states.^10,14
• Symptoms must be evaluated after a period of sobriety adequate to the drug's pharmacokinetics; persistence beyond the physiologic effect supports a primary mood disorder.¹³

Medical mimics

• Hyperthyroidism, Cushing syndrome, systemic lupus erythematosus, and HIV can produce mania-like states.¹⁴
• Neurologic causes include multiple sclerosis, frontal or temporal lobe lesions (stroke, tumor, trauma), Huntington disease, and seizure disorders, particularly complex partial seizures of temporal origin.¹⁴
• Late-onset mania (after age 50) without prior history should prompt neurologic and metabolic workup, including imaging.¹⁴

Diagnosis is clinical and longitudinal. Confirmatory laboratory tests do not exist; investigations are directed at ruling out medical mimics and at baseline screening before pharmacotherapy.

History elements (mandatory)

• Detailed mood-episode timeline, including age of onset, episode count, polarity, duration, severity, and inter-episode functioning.¹⁴
• Sleep history with attention to decreased need for sleep distinct from insomnia.¹⁴
• Psychotic, suicidal, and homicidal symptom inquiry, including history of attempts and means.^6,14
• Substance use history with quantity, frequency, and temporal relationship to mood symptoms.¹⁴
• Medication history, including antidepressant trials and any activation, agitation, or hypomania during treatment.¹⁴
• Family history of mood disorders, psychosis, suicide, and lithium response.^3,7
• Trauma, perinatal status, and developmental history; obstetric history in women of reproductive age.¹⁴

Collateral information

• Collateral from family or partners is often diagnostic, since patients in mania frequently lack insight and patients in depression underreport prior elevated states.¹⁴

Validated rating scales

• Young Mania Rating Scale (YMRS): clinician-rated, 11 items, the standard scale for manic severity in trials and increasingly in clinical use.¹⁷
• Mood Disorder Questionnaire (MDQ): 13-item self-report screen for lifetime bipolar spectrum; sensitivity around 70% and specificity around 90% in validation samples.¹⁸
• Hypomania Checklist-32 (HCL-32): self-report screen with higher sensitivity for Bipolar II.¹⁸
• PHQ-9 and Hamilton Depression Rating Scale (HAM-D) or Montgomery-Asberg Depression Rating Scale (MADRS) for depressive severity; PHQ-9 alone does not differentiate bipolar from unipolar depression.¹⁹
• Columbia Suicide Severity Rating Scale (C-SSRS) for structured suicide risk assessment.⁶

Physical exam and labs (baseline and periodic):

• General physical and neurologic exam, including vital signs, weight, BMI, and waist circumference.^14,20
• CBC, comprehensive metabolic panel, fasting lipids, fasting glucose or HbA1c, and TSH at baseline.²⁰
• Pregnancy test in any patient of reproductive potential before initiating teratogenic agents (valproate, carbamazepine, lamotrigine to a lesser degree).^20-21
• ECG before lithium and before high-dose antipsychotics, particularly in patients over 40 or with cardiac risk factors.²⁰
• Toxicology screen at presentation when substance use is suspected.¹⁴
• Imaging is not routine but is indicated for first manic episode at unusual ages, focal neurologic findings, or atypical course.¹⁴

What not to order

• Routine genetic, autoimmune, or neuroimaging panels in a typical-onset, unremarkable presentation; the diagnostic yield is low and the cost is real.¹⁴

Treatment is staged by phase: acute mania, acute bipolar depression, and maintenance. The same drugs do not work equally well in each phase, and the maintenance regimen may differ from the acute one. Apply GRADE-calibrated language: lithium has the strongest cumulative evidence base; several second-generation antipsychotics, valproate, and certain combinations have moderate-to-strong evidence in specific phases.

Pharmacotherapy

• Acute mania, first-line monotherapy: lithium, valproate (divalproex), or a second-generation antipsychotic such as risperidone, olanzapine, quetiapine, aripiprazole, asenapine, or cariprazine; combination of lithium or valproate with an antipsychotic outperforms monotherapy in moderate-to-severe mania.^22-23
• Lithium target serum level for acute mania is 0.8-1.2 mEq/L; for maintenance, 0.6-1.0 mEq/L is commonly recommended, with the higher end of the range associated with better prophylaxis but more adverse effects.²⁴
• Valproate is commonly recommended for mixed features and rapid cycling, with a typical serum level of 50-125 mcg/mL for acute mania.^22,24
• Carbamazepine is a second-line option for mania, useful when first-line agents have failed or are contraindicated; oxcarbazepine has limited evidence.^22,24
• Acute bipolar depression, first-line: quetiapine, lurasidone, cariprazine, olanzapine-fluoxetine combination, and lumateperone all have evidence supporting efficacy; lithium and lamotrigine are appropriate options with smaller acute effect sizes.^25-26
• Antidepressant monotherapy is not recommended in Bipolar I depression because of the risk of treatment-emergent mania and mood destabilization; if used, antidepressants should be combined with an antimanic agent and discontinued after remission in most cases.^25-26
• Maintenance, first-line: lithium has the most consistent evidence for relapse prevention, with particular efficacy against manic relapse and a documented anti-suicide effect; quetiapine, valproate, lamotrigine (better against depressive relapse), aripiprazole, and several long-acting injectable antipsychotics are also supported.^27-28
• Lamotrigine is commonly recommended for maintenance prevention of depressive episodes but is not effective for acute mania; titration must be slow because of the risk of Stevens-Johnson syndrome.^26,28

Psychotherapy

• Structured psychoeducation reduces relapse rates and improves adherence and is commonly recommended as a baseline intervention for every patient with Bipolar I.²⁹
• Cognitive-behavioral therapy, family-focused therapy, and interpersonal and social rhythm therapy each have evidence for reduction in relapse and improvement in functioning when added to pharmacotherapy.^29-30
• Psychotherapy is adjunctive, not a substitute for mood-stabilizing pharmacotherapy in Bipolar I.²⁹

Neuromodulation

• Electroconvulsive therapy (ECT) is highly effective for severe, treatment-resistant, catatonic, or peripartum mania and bipolar depression, and is a first-line option when rapid response is required or when pregnancy precludes pharmacotherapy.³¹
• Repetitive transcranial magnetic stimulation has limited and mixed evidence in bipolar depression and is not routinely recommended.³¹

Adjunctive

• Benzodiazepines (lorazepam, clonazepam) are useful for short-term agitation, sleep restoration, and as bridging therapy until a primary antimanic agent takes effect.²²
• Sleep-wake regulation, substance use treatment, and weight and metabolic monitoring are essential components of long-term care.^20,29
• Pharmacogenomic testing is not routinely recommended for first-line drug selection.⁹

Pharmacotherapy for Bipolar I produces durable benefit but at meaningful long-term cost: weight gain, metabolic syndrome, renal and thyroid effects, neurologic adverse effects, and teratogenicity all shape decision-making. Evidence quality varies widely across phase and agent.

Common adverse effects

• Weight gain and metabolic syndrome are common with olanzapine, quetiapine, valproate, and (to a lesser degree) lithium and risperidone, contributing to long-term cardiovascular risk.^20,32
• Sedation, cognitive slowing, and tremor are common with lithium and valproate at therapeutic levels.^24,32
• Sexual dysfunction is underrecognized and contributes to non-adherence with several second-generation antipsychotics and antidepressants when added.³²

Serious or rare adverse effects

• Lithium toxicity occurs with levels above approximately 1.5 mEq/L and is precipitated by dehydration, NSAIDs, ACE inhibitors, thiazides, and renal impairment; severe toxicity (>2.0 mEq/L) is a medical emergency requiring hemodialysis.^24,33
• Long-term lithium use is associated with chronic kidney disease in a minority of patients, hypothyroidism in roughly 20%, and hyperparathyroidism with hypercalcemia.^24,33
• Valproate carries risks of hepatotoxicity, pancreatitis, hyperammonemic encephalopathy, and thrombocytopenia.³²
• Lamotrigine is associated with Stevens-Johnson syndrome and toxic epidermal necrolysis, particularly with rapid titration or co-administration with valproate, which doubles lamotrigine levels.³²
• Carbamazepine causes hyponatremia, agranulocytosis, aplastic anemia, and serious dermatologic reactions, with elevated risk of Stevens-Johnson syndrome in HLA-B*1502 carriers.³²
• Second-generation antipsychotics carry small but real risks of tardive dyskinesia, neuroleptic malignant syndrome, QTc prolongation, and hyperprolactinemia.³²

Monitoring burden and discontinuation

• Lithium requires periodic monitoring of serum level, renal function, TSH, and calcium, with frequency proportional to time on drug and clinical stability.²⁴
• Valproate and carbamazepine require periodic CBC, liver function tests, and serum levels; carbamazepine auto-induces its own metabolism, requiring level rechecks after dose changes.³²
• Abrupt discontinuation of lithium is associated with a high rate of relapse and may produce refractoriness on rechallenge in a subset of patients; taper slowly over weeks to months when discontinuation is needed.²⁷

Limitations of the evidence base

• Maintenance trials commonly enroll patients who responded to acute treatment with the same agent, biasing efficacy estimates upward (enrichment design).²⁷
• Long-term head-to-head comparisons across agents are limited, and most maintenance data extend 1-2 years rather than the lifetime course relevant to patients.²⁷
• Patients with active substance use, severe medical comorbidity, suicidal ideation, or psychosis are often excluded from RCTs, limiting external validity.²⁸

Phase, age, and reproductive status drive treatment selection more than any other factors. Default first-line recommendations require modification in several populations.

Pediatric

• Bipolar I can be diagnosed in adolescents using the same DSM-5-TR criteria; chronic irritability without discrete episodes is more consistent with disruptive mood dysregulation disorder.^14,34
• Risperidone, aripiprazole, quetiapine, asenapine, and olanzapine carry FDA pediatric mania indications; lithium is approved from age 7 for mania.³⁴
• Children and adolescents are more vulnerable to weight gain and metabolic effects of second-generation antipsychotics, requiring closer metabolic monitoring.³⁴

Geriatric

• New-onset mania after age 50 should prompt evaluation for medical, neurologic, or substance contributors; secondary mania is more common than primary in this group.¹⁴
• Lithium dosing should be reduced because of age-related decline in renal clearance and increased CNS sensitivity; target levels of 0.4-0.8 mEq/L are commonly recommended.²⁴
• Drug-drug interactions, falls, and cognitive effects all argue for conservative dosing and close monitoring in older adults.^24,32

Perinatal

• Pregnancy in Bipolar I carries a high relapse risk, particularly with discontinuation of mood stabilizers; postpartum is the highest-risk period for severe episodes including postpartum psychosis.³⁵
• Valproate and carbamazepine are major teratogens and should be avoided in pregnancy when possible; lithium carries a small absolute increase in cardiac malformations (Ebstein anomaly), historically overstated, with modern estimates around 1-2% absolute risk.³⁵
• Lamotrigine and several second-generation antipsychotics have more reassuring reproductive safety data and are reasonable options when continuation of treatment is required.³⁵
• Postpartum prophylaxis with lithium or an antipsychotic substantially reduces postpartum relapse and is commonly recommended for women with Bipolar I.³⁵
• ECT is safe and effective in pregnancy and is appropriate when rapid response is required or pharmacotherapy is contraindicated.^31,35

Comorbid medical illness

• Renal disease, thyroid disease, and pregnancy each modify lithium suitability; cardiac disease modifies antipsychotic selection because of QTc effects.^24,32
• Hepatic disease modifies valproate and carbamazepine suitability.³²

Comorbid substance use

• Untreated substance use sharply worsens outcome; integrated treatment of mood and substance disorders outperforms sequential treatment.⁴
• Lithium, valproate, and several second-generation antipsychotics retain efficacy in patients with substance use, though adherence is typically poorer.⁴

Cultural considerations

• Diagnostic thresholds and treatment access vary internationally; cultural expression of grandiosity, religiosity, and risk-taking should be interpreted within the patient's reference group.^2,14

Bipolar I is a chronic, recurrent illness with substantial inter-episode morbidity. With treatment, most patients achieve symptomatic remission of acute episodes; functional recovery lags behind syndromal recovery and is the more relevant long-term metric.

Course

• Most patients have multiple lifetime episodes; over 90% who have a single manic episode go on to have additional episodes.¹⁴
• Patients spend approximately three times more weeks depressed than manic over the long course, with subsyndromal symptoms common between episodes.^14,16
• Cognitive impairment, particularly in attention, executive function, and verbal memory, persists in a substantial minority during euthymia.¹⁶

Response and remission

• Acute mania: remission rates with first-line monotherapy are approximately 40-60% at 3-4 weeks; combination therapy raises response rates by approximately 10-15 percentage points.^22-23
• Acute bipolar depression: response rates with quetiapine, lurasidone, and cariprazine are roughly 50-60%, with placebo response rates of 30-40%.^25-26
• Maintenance: lithium prevents approximately one-third of relapses compared with placebo over 1-2 years, with greater protection against manic than depressive relapse.^27-28

Suicide

• Lifetime suicide risk is approximately 6-10%; lithium is associated with a reduction in suicide and all-cause mortality compared with other mood stabilizers in observational and meta-analytic data.^5-6,27

Functional outcome

• Approximately one-third of patients achieve sustained functional recovery, one-third have intermediate outcomes, and one-third have poor outcomes despite adequate treatment.¹⁶
• Predictors of poorer outcome include early onset, psychotic features, mixed features, rapid cycling, comorbid substance use, and poor adherence.^14,16

Acute mania, severe mixed states, and bipolar depression with suicidal ideation are the principal psychiatric emergencies in Bipolar I. Threshold for hospitalization should be low when judgment, agitation, or suicidality is significant.

Hospitalization criteria

• Acute mania with impaired judgment, dangerous behavior, psychosis, or inability to care for self warrants inpatient admission, often involuntarily.¹⁴
• Severe depressive episode with suicidal ideation, psychotic features, or inability to function is an indication for admission.^6,14
• Mixed features with suicidality carry particularly high acute risk and should lower the threshold for admission.^6,14

Suicide risk markers

• Past attempts (the strongest single predictor), mixed features, hopelessness, comorbid substance use, recent discharge, and access to means.⁶
• Structured assessment with the C-SSRS does not replace clinical judgment but supports documentation and stratification.⁶

Acute agitation management

• Verbal de-escalation and environmental modification are first steps; offer oral medication before parenteral when feasible.³⁶
• Pharmacologic options include intramuscular or oral haloperidol, olanzapine, ziprasidone, or aripiprazole; benzodiazepines (lorazepam) alone or in combination may be used.³⁶
• Avoid combining intramuscular olanzapine with parenteral benzodiazepines because of the risk of cardiorespiratory depression.³⁶

Lithium toxicity

• Mild toxicity (1.5-2.0 mEq/L): coarse tremor, ataxia, nausea, vomiting; hold drug, hydrate, identify precipitant.³³
• Moderate (2.0-2.5 mEq/L): confusion, dysarthria, myoclonus; hospitalize, consider hemodialysis if symptomatic or renal impairment.³³
• Severe (>2.5 mEq/L) or symptomatic at lower levels: hemodialysis is indicated; toxicity can persist after serum levels normalize because of slow CNS redistribution.³³

Several long-standing debates shape clinical decision-making in Bipolar I. None has a definitive answer; clinicians should know the evidence each side cites.

Antidepressants in bipolar depression

• Whether antidepressants benefit Bipolar I depression when added to a mood stabilizer remains contested; the largest trials show modest or no benefit, and most international guidelines recommend against monotherapy and against routine use even as adjuncts.^25-26
• A subset of patients appears to derive durable benefit from antidepressants without destabilization, but no reliable predictor identifies this group prospectively.²⁵

Lithium versus alternatives for first-line maintenance

• Lithium has the strongest cumulative evidence and a documented anti-suicide effect, but its real-world use has declined in favor of valproate and second-generation antipsychotics, in part because of monitoring burden and tolerability concerns.^27-28
• Several international guidelines continue to position lithium as the preferred first-line maintenance agent.²⁸

Bipolar spectrum and diagnostic boundaries

• The boundary between Bipolar II and Bipolar I, between bipolar disorder and major depressive disorder with mood lability, and between bipolar and borderline personality disorder remains an area of clinical and nosologic disagreement.^14,16
• Pediatric bipolar disorder, particularly in prepubertal children, remains controversial; the introduction of disruptive mood dysregulation disorder in DSM-5 was intended to reduce overdiagnosis of bipolar disorder in chronically irritable children.³⁴

Neuroprogression and kindling

• Whether recurrent episodes drive progressive neural and cognitive change (neuroprogression) is supported by some longitudinal imaging data and challenged by methodologic concerns about cohort effects and treatment exposure.^10-11

Ketamine and emerging treatments

• Ketamine and esketamine show rapid antidepressant effects in bipolar depression in small trials, but durability, mania risk, and place in therapy are unsettled.¹¹
• Lumateperone received FDA approval for bipolar depression as monotherapy and adjunct based on RCTs; comparative effectiveness against established agents is not yet established.²⁶

• Bipolar I requires at least one lifetime manic episode; depressive and hypomanic episodes are not required for the diagnosis.¹³
• A manic episode lasts at least one week (or any duration if hospitalization is required) with at least three associated symptoms (four if mood is only irritable).¹³
• Antidepressant-emergent mania that persists beyond the drug's physiologic effect counts as a true manic episode and supports a Bipolar I diagnosis.¹³
• Lifetime prevalence of Bipolar I is approximately 1%, with a 1:1 sex ratio and mean onset in the late teens to mid-twenties.^1,3
• Lifetime suicide risk is approximately 6-10%, and lithium is associated with reduced suicide and all-cause mortality.^5-6,27
• Lithium therapeutic range for maintenance is 0.6-1.0 mEq/L and for acute mania 0.8-1.2 mEq/L.²⁴
• Eight baseline labs before lithium: TFTs, BUN, creatinine, electrolytes, pregnancy test, weight, ECG, urinalysis.^20,24
• Lithium toxicity above 2.0 mEq/L is a medical emergency; hemodialysis is indicated for severe or symptomatic toxicity.³³
• Valproate is highly teratogenic (neural tube defects, neurodevelopmental effects) and should be avoided in patients of childbearing potential when alternatives exist.³⁵
• Lamotrigine prevents depressive relapse but is not effective for acute mania and requires slow titration to reduce Stevens-Johnson syndrome risk.^26,28
• Quetiapine, lurasidone, cariprazine, olanzapine-fluoxetine combination, and lumateperone have FDA-supported evidence for acute bipolar I depression.^25-26
• ECT is highly effective for severe, treatment-resistant, catatonic, or peripartum mania and depression and is safe in pregnancy.^31,35
• Postpartum is the highest-risk period for severe mood episodes and postpartum psychosis in Bipolar I.³⁵
• Mixed features predict greater suicide risk and poorer response to antidepressant monotherapy.^13-14
• Most patients with Bipolar I spend more weeks depressed than manic over the long course, which has direct treatment implications.^14,16

No external funding. No conflicts of interest declared. Peer-review status: pending.